Article

Assessment of blood-based tumor mutational burden on clinical outcomes in advanced breast and prostate cancer treated with immune checkpoint inhibitors

2024-05-29

Abstract excerpt

<title>Abstract</title> <p>Background Breast and prostate are in general, less responsive to Immune checkpoint inhibitors (ICIs). Tumor mutation burden (TMB) has emerged as a predictive biomarker of response to ICIs and new technologies for evaluating TMB, including liquid biopsy, are now available. We aimed to investigate the role of blood TMB in predicting response to ICIs and its association with genomics alt...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a2a4dab8-db81-59f9-a47f-a310bf254128
DOI: 10.21203/rs.3.rs-4339204/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Assessment of blood-based tumor mutational burden on clinical outcomes in advanced breast and prostate cancer treated with immune checkpoint inhibitorsDOI 10.21203/rs.3.rs-4339204/v1Read

Validity and utility of blood tumor mutational burden is dependent on circulating tumor DNA shedSemantic proximity Read

TMBpred: A bioinformatics tool for precise prediction of the Tumor Mutation Burden in 14 cancer typesSemantic proximity Read

Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.Semantic proximity Read

Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure.Semantic proximity Read

Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREENSemantic proximity Read

Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkersSemantic proximity Read

Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer ApproachSemantic proximity Read

Prevalence and molecular features of TMB-high and MSI-high breast cancer assessed by gene panel testingSemantic proximity Read

Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivitySemantic proximity Read

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.Semantic proximity Read

The Impact of TMB on Immunotherapy Protocols: A Comprehensive Analysis of Four Major CancersSemantic proximity Read

Genomic Landscape of Circulating-Tumor DNA in a Diverse Cohort of Metastatic Breast Cancer Patients.Semantic proximity Read